Polyester nanomedicines targeting inflammatory signaling pathways for cancer therapy

The growth of cancerous cells and their responses towards substantial therapeutics are primarily controlled by inflammations (acute and chronic) and inflammation-associated products, which either endorse or repress tumor progression. Additionally, major signaling pathways, including NF-Kappa B, STAT3, inflammation-causing factors (cytokines, TNF-alpha, chemokines), and growth-regulating factors (VEGF, TGF-beta), are vital regulators responsible for the instigation and resolution of inflammations. Moreover, the conventional chemotherapeutics have exhibited diverse limitations, including poor pharmacokinetics, unfavorable chemical properties, poor target -ability to the disease-specific disease leading to toxicity; thus, their applications are restricted in inflammation mediated cancer therapy. Furthermore, nanotechnology has demonstrated potential benefits over conventional chemotherapeutics, such as it protected the incorporated drug/bioactive moiety from enzymatic degradation within the systemic circulation, improving the physicochemical properties of poorly aqueous soluble chemo-therapeutic agents, and enhancing their targetability in specified carcinogenic cells rather than accumulating in the healthy cells, leading reduced cytotoxicity. Among diverse nanomaterials, polyester-based nanoparticulate delivery systems have been extensively used to target various inflammation-mediated cancers. This review summarizes the therapeutic potentials of various polyester nanomaterials (PLGA, PCL, PLA, PHA, and others) -based delivery systems targeting multiple signaling pathways related to inflammation-mediated cancer.

Automated summary

Inflammations play a crucial role in the growth and treatment of cancer cells. Conventional chemotherapeutics have limitations, while nanotechnology offers potential benefits. Polyester-based nanoparticulate delivery systems have been extensively studied for targeting inflammation-mediated cancers.